These results come from the second stage of Xortx’s Pharmacokinetics Bridging Study titled XRX-OXY-101. The trial tested the effects of the company’s “proprietary oxypurinol formulation” in patients that were fed compared to those in a “fasted state.”
According to the Xortx, the company saw “improved bioavailability findings” from the clinical trial in patients that were fed as compared to fasted. This data will help with the company’s upcoming Phase 3 registration trial to treat autosomal dominant polycystic kidney disease (ADPKD).
CEO Dr. Allen Davidoff said the following about the results:
“Pharmacokinetic modeling of both of these data sets will provide key information regarding the safe and effective administration of oxypurinol and guide decision making as we plan and execute development of the XRx-008 program clinical and commercial development. We look forward to the initiation of dosing of Part 3 of the XRX-OXY-101 in the near future.”
News of theses positive clinical trial results are bringing heavy trading to XRTX stock today. As of this writing, more than 3 million shares have changed hands. That’s a massive leap over the company’s daily average trading volume of about 421,000 shares.
XRTX stock started off strong this morning with a roughly 30% gain. However, shares are currently down 4% as of late this morning and continue to fluctuate.
Investors seeking out more of the latest stock market news will want to keep reading!
We’ve got all of the hottest stock market news moving shares this morning. That includes what’s happening with Mullen Automotive (NASDAQ:MULN), Cineworld (OTCMKTS:CNWGY) and Social Capital Suvretta Holdings (NASDAQ:DNAA) stock. You can find out more at the following links!
More Monday Stock Market News
- Dear MULN Stock Fans, Mark Your Calendars for an October Launch
- CNWGY Stock Alert: What to Know as Cineworld Faces Possible Bankruptcy
- DNAA Stock Races 200% Higher as Akili SPAC Merger Closes
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.